ES2905525T3 - Alteración de poblaciones microbianas y modificación de la microbiota - Google Patents

Alteración de poblaciones microbianas y modificación de la microbiota Download PDF

Info

Publication number
ES2905525T3
ES2905525T3 ES16719873T ES16719873T ES2905525T3 ES 2905525 T3 ES2905525 T3 ES 2905525T3 ES 16719873 T ES16719873 T ES 16719873T ES 16719873 T ES16719873 T ES 16719873T ES 2905525 T3 ES2905525 T3 ES 2905525T3
Authority
ES
Spain
Prior art keywords
sequence
vector
host
host cell
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16719873T
Other languages
English (en)
Spanish (es)
Inventor
Jasper Clube
Morten Sommer
Christian Grøndahl
Der Helm Eric Van
Ruben Vazquez-Uribe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNIPR Technologies Ltd
Original Assignee
SNIPR Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57217569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2905525(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1507776.1A external-priority patent/GB201507776D0/en
Priority claimed from GBGB1507774.6A external-priority patent/GB201507774D0/en
Priority claimed from GBGB1507775.3A external-priority patent/GB201507775D0/en
Priority claimed from GBGB1507773.8A external-priority patent/GB201507773D0/en
Priority claimed from GBGB1508461.9A external-priority patent/GB201508461D0/en
Priority claimed from GBGB1509366.9A external-priority patent/GB201509366D0/en
Priority claimed from GBGB1510891.3A external-priority patent/GB201510891D0/en
Priority claimed from GBGB1518402.1A external-priority patent/GB201518402D0/en
Priority claimed from GBGB1600418.6A external-priority patent/GB201600418D0/en
Priority claimed from GB1600417.8A external-priority patent/GB2531454A/en
Application filed by SNIPR Technologies Ltd filed Critical SNIPR Technologies Ltd
Publication of ES2905525T3 publication Critical patent/ES2905525T3/es
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/60—Isolated nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
ES16719873T 2015-05-06 2016-05-03 Alteración de poblaciones microbianas y modificación de la microbiota Active ES2905525T3 (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB1507774.6A GB201507774D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (2)
GBGB1507775.3A GB201507775D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (3)
GBGB1507773.8A GB201507773D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (1)
GBGB1507776.1A GB201507776D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (4)
GBGB1508461.9A GB201508461D0 (en) 2015-05-17 2015-05-17 Products uses and methods (4.2)
GBGB1509366.9A GB201509366D0 (en) 2015-05-31 2015-05-31 Products, uses & methods (6)
GBGB1510891.3A GB201510891D0 (en) 2015-06-20 2015-06-20 Products, uses & methods (7)
GBGB1518402.1A GB201518402D0 (en) 2015-10-17 2015-10-17 Products, uses & methods (8)
GBGB1600418.6A GB201600418D0 (en) 2016-01-10 2016-01-10 Products, uses & methods (1.2)
GB1600417.8A GB2531454A (en) 2016-01-10 2016-01-10 Recombinogenic nucleic acid strands in situ
PCT/EP2016/059803 WO2016177682A1 (en) 2015-05-06 2016-05-03 Altering microbial populations & modifying microbiota

Publications (1)

Publication Number Publication Date
ES2905525T3 true ES2905525T3 (es) 2022-04-11

Family

ID=57217569

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16719873T Active ES2905525T3 (es) 2015-05-06 2016-05-03 Alteración de poblaciones microbianas y modificación de la microbiota

Country Status (17)

Country Link
US (30) US9701964B2 (https=)
EP (12) EP3711488A1 (https=)
JP (5) JP2018515138A (https=)
KR (4) KR20230174291A (https=)
CN (3) CN107667173A (https=)
AU (6) AU2016257306B2 (https=)
CA (1) CA2984975A1 (https=)
DE (1) DE112016002056T5 (https=)
DK (1) DK3291679T3 (https=)
ES (1) ES2905525T3 (https=)
IL (4) IL293646B2 (https=)
NZ (1) NZ738068A (https=)
PL (1) PL3291679T3 (https=)
RU (1) RU2017142352A (https=)
SG (1) SG11201708706YA (https=)
SI (1) SI3291679T1 (https=)
WO (1) WO2016177682A1 (https=)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
US11135273B2 (en) 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
CN105492611A (zh) 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
JP6712948B2 (ja) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
JP2017512481A (ja) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP3186375A4 (en) 2014-08-28 2019-03-13 North Carolina State University Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
EP3711488A1 (en) 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
EA201792663A1 (ru) * 2015-05-29 2018-04-30 Норт Каролина Стейт Юниверсити Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
WO2016205276A1 (en) 2015-06-15 2016-12-22 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
TWI906646B (zh) 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的ｃｒｉｓｐｒ酶突變
EP3356533A1 (en) 2015-09-28 2018-08-08 North Carolina State University Methods and compositions for sequence specific antimicrobials
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11267738B2 (en) * 2017-04-24 2022-03-08 Microbe Detectives Llc Method of using microbial DNA sequencing in recovering renewable resources from wastewater and other waste streams
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
JP2020525049A (ja) * 2017-06-25 2020-08-27 エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 微生物集団の変更及び細菌叢の改変
EP3651796A4 (en) * 2017-07-12 2021-06-30 The Brigham and Women's Hospital, Inc. LIVE ATTENUATED CHOLERA VACCINE WITH PROBIOTIC PROPERTIES
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
GB201712733D0 (en) * 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019055582A1 (en) * 2017-09-12 2019-03-21 Ubabiologix Corp. COMPOSITIONS AND METHODS FOR SANITATION OF WASTE WATER
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
CA3082450A1 (en) 2017-11-21 2019-05-31 Crispr Therapeutics Ag Materials and methods for treatment of autosomal dominant retinitis pigmentosa
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN109899053B (zh) * 2017-12-08 2022-02-01 中国石油天然气股份有限公司 钻井井场的确定方法、装置及计算机可读存储介质
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN109971778B (zh) * 2017-12-27 2022-11-18 北京蓝晶微生物科技有限公司 一种在盐单胞菌中快速基因编辑的载体组合及其应用
CN108410880B (zh) * 2018-01-26 2021-10-22 昆明理工大学 一种丹波黑大豆柠檬酸转运蛋白基因及其应用
KR20210006344A (ko) 2018-03-25 2021-01-18 에스엔아이피알 바이옴 에이피에스. 미생물 감염의 치료 및 예방
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3099316A1 (en) * 2018-05-04 2019-11-07 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
CN108588050B (zh) * 2018-05-14 2021-06-25 北京艾克伦医疗科技有限公司 Dna聚合酶以及核酸检测方法和试剂盒
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
WO2019227080A1 (en) * 2018-05-25 2019-11-28 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3821021A4 (en) * 2018-07-11 2021-09-15 Société de commercialisation des produits de la recherche appliquée SOCPRA Sciences Santé et Humaines s.e.c. BACTERIAL CONJUGATIVE SYSTEM AND THERAPEUTIC USES THEREOF
CN109136128B (zh) * 2018-08-23 2021-07-16 国家海洋局第一海洋研究所 一种副球菌及其筛选方法和在合成银纳米颗粒中的应用
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
WO2020072248A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system
WO2020072254A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for killing target cells
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN111119818B (zh) * 2018-10-30 2022-04-12 中国石油化工股份有限公司 一种油藏内源功能微生物定向调控的方法
US20220403367A1 (en) * 2019-01-11 2022-12-22 The Trustees Of Columbia University In The City Of New York Microbiome engineering through engineered mobile genetic elements
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
WO2020176624A1 (en) * 2019-02-26 2020-09-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Probiotics and probiotic compositions having modified carbohydrate metabolism
BR112021017655A2 (pt) * 2019-03-07 2021-11-16 Univ Columbia Método e sistema de integração de dna guiada por rna usando transposons tipo tn7
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110499353B (zh) * 2019-08-09 2023-11-07 佛山市第四人民医院(佛山市结核病防治所) 一种用于结核耐药诊断的微生物标志物及其应用
GB201913045D0 (en) * 2019-09-10 2019-10-23 Univ Oxford Innovation Ltd Biofilm transformation
CN110596364B (zh) * 2019-09-12 2020-06-23 江南大学 一种前列腺特异性抗原检测的比率电化学传感器的构建方法及其应用
JP2022548735A (ja) * 2019-09-18 2022-11-21 アンシリア， インコーポレイテッド マイクロバイオーム調節のための組成物及び方法
US20210095273A1 (en) * 2019-09-30 2021-04-01 Sigma-Aldrich Co. Llc Modulation of microbiota compositions using targeted nucleases
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN114981408A (zh) * 2019-11-06 2022-08-30 洛可斯生物科学公司 Crispr cas系统和溶原性模块
US20230001020A1 (en) * 2019-11-25 2023-01-05 Baylor College Of Medicine Selective expansion of gene-targeted cells
WO2021119594A1 (en) * 2019-12-13 2021-06-17 The Regents Of The University Of California Reducing antibiotic resistance in bacteria using pro-active genetics
DE102020101859A1 (de) * 2020-01-27 2021-07-29 Oxana Karpf Verfahren zur Reduktion der Population mindestens einer adipogenen Bakterienart umfassend Bakteriophagen sowie Bakteriophagen und deren Verwendung
CA3171941A1 (en) * 2020-03-16 2021-09-23 Joseph E. Peters Compositions and methods comprising improved guide rnas
EP4127181A4 (en) * 2020-03-27 2024-04-10 The Trustees of Columbia University in the City of New York GENOME ENGINEERING USING CRISPR-RNA-GUIDED INTEGRASES
JP7488096B2 (ja) * 2020-04-16 2024-05-21 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
JP7504650B2 (ja) * 2020-04-16 2024-06-24 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
JP7527830B2 (ja) * 2020-04-16 2024-08-05 旭化成株式会社 セルロース繊維乾燥体の製造方法、及び樹脂複合体の製造方法
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
WO2021231689A1 (en) * 2020-05-14 2021-11-18 Chan Zuckerberg Biohub, Inc. Phage-mediated delivery of genes to gut microbiome
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
ES2890491T1 (es) * 2020-06-12 2022-01-20 Eligo Bioscience Descolonización específica de bacterias resistentes a los antibióticos para fines profilácticos
CA3184278A1 (en) * 2020-06-16 2021-12-23 Dsm Ip Assets B.V. A composition for reducing the risk of urinary tract infection and vaginal infection in women
CN111849822A (zh) * 2020-07-28 2020-10-30 上海海洋大学 对抗菌素敏感的非o1/o139型霍乱弧菌菌株及应用
WO2022081428A1 (en) * 2020-10-16 2022-04-21 Nubiyota Llc Bacterial compositions and methods of use thereof for treatment of metabolic syndrome
CN113201531B (zh) * 2021-04-27 2023-06-27 隆平生物技术(海南)有限公司 转基因玉米事件lw2-1及其检测方法
FR3136482A1 (fr) * 2021-08-01 2023-12-15 Snipr Biome Aps Ingenierie du microbiote
US20250084398A1 (en) * 2021-08-02 2025-03-13 Trobix Bio Ltd Systems for modulating drug metabolism by cells, methods and compositions thereof
WO2023159028A1 (en) 2022-02-15 2023-08-24 10X Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
KR20250031203A (ko) 2022-06-29 2025-03-06 에스엔아이피알 바이옴 에이피에스. 이 콜라이 세포의 표적화
WO2024023820A1 (en) * 2022-07-25 2024-02-01 Trobix Bio Ltd Systems for modulating microbiome target cells, methods and compositions thereof
EP4604969A1 (en) * 2022-10-17 2025-08-27 Locus Biosciences, Inc. Staphylococcus phage compositions and cocktails thereof
CN116042450B (zh) * 2022-11-03 2024-10-01 杭州秀川科技有限公司 一株高效降解苯胺类物质的陶厄氏菌及其应用
CN116058432B (zh) * 2023-03-02 2023-06-16 莱芜泰禾生化有限公司 一种柠檬酸菌丝渣微生物饲料添加剂及其制备方法和应用
CN116694535B (zh) * 2023-07-20 2024-08-23 四川大学 一种戊糖乳杆菌w19及其应用
GB202402011D0 (en) 2024-02-14 2024-03-27 Snipr Biome Aps A novel type of crispr/cas system
WO2025093778A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota
JPWO2025100495A1 (https=) * 2023-11-09 2025-05-15
WO2025132815A1 (en) 2023-12-20 2025-06-26 Novozymes A/S Novel cas nucleases and polynucleotides encoding the same

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US928A (en) * 1838-09-19 Eccentbic bbake eob abbesting the motion of bailboad-cabs
US3003323A (en) 1958-01-29 1961-10-10 Armco Steel Corp Composite pile connector
US4626504A (en) 1983-07-01 1986-12-02 Lubrizol Genetics, Inc. DNA transfer vector for gram-negative bacteria
SE8505027D0 (sv) 1985-10-24 1985-10-24 Kabigen Ab A lytic virulent phage, a hostcell containing same and a process for protein production
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE4208785A1 (de) 1992-03-19 1993-09-23 Degussa Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen
EP0665852A1 (en) 1993-07-09 1995-08-09 Amgen Boulder Inc. Recombinant ctla4 polypeptides and methods for making the same
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
ATE313341T1 (de) 2000-01-11 2006-01-15 Intralytix Inc Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen
WO2003060066A2 (en) 2001-11-07 2003-07-24 Musc Foundation For Research Development Nucleic acid delivery and expression
CA2396611A1 (en) 2002-07-31 2004-01-31 Plant Bioscience Limited Materials and methods for generating genetic disruptions in bacterial cells
HRP20120845T1 (hr) 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
HRP20170342T1 (hr) 2003-07-24 2017-05-19 Innate Pharma S.A. Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
EP1677834B1 (en) 2003-10-06 2014-01-08 Gangagen, Inc. Defined dose therapeutic phage
AU2005324479A1 (en) 2004-04-07 2006-07-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reporter plasmid phage packaging system for detection of bacteria
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
CN101103043A (zh) 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
DK2341149T3 (en) 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
US8445639B2 (en) 2006-05-15 2013-05-21 Avidbiotics Corporation Recombinant bacteriophage and methods for their use
EP2102350A4 (en) * 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
CN105037549B (zh) 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
CN101688241B (zh) 2007-03-02 2015-01-21 杜邦营养生物科学有限公司 具有改善的噬菌体抗性的培养物
WO2008121830A2 (en) 2007-03-30 2008-10-09 National Research Council Of Canada Phage receptor binding proteins for antibacterial therapy and other novel uses
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
JP5344895B2 (ja) * 2008-12-10 2013-11-20 矢崎総業株式会社 充電監視装置
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
US8241498B2 (en) 2009-03-28 2012-08-14 Phage Biocontrol Research, Llc Process for remediating biofouling in water systems with virulent bacteriophage
JP2010285425A (ja) 2009-05-12 2010-12-24 Fujifilm Corp 腸内細菌叢構成比率調整剤
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8252576B2 (en) 2010-08-11 2012-08-28 Phage Biocontrol Research, Llc Use of prokaryote viruses to remediate bio-fouling
CN103261213A (zh) * 2010-10-20 2013-08-21 杜邦营养生物科学有限公司 乳球菌CRISPR-Cas序列
EP2643350A4 (en) 2010-11-22 2015-01-07 Innate Pharma Sa TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013025119A1 (ru) 2011-08-18 2013-02-21 Roschin Evgeniy Mikhailovich Способ определения расположения протетической верхней плоскости у пациентов
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
CN107858333B (zh) 2011-10-28 2022-05-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013165921A2 (en) 2012-04-30 2013-11-07 Sonomaceuticals, Llc Therapeutic use of chardonnay seed products
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2013187556A1 (en) 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10025647B2 (en) 2012-06-30 2018-07-17 Intel Corporation Memory poisoning with hints
US20150290244A1 (en) 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9460205B2 (en) * 2012-07-20 2016-10-04 Google Inc. Crowdsourced video collaboration
AU2013293270B2 (en) 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
DK2895012T3 (en) 2012-09-11 2018-01-22 Thylabisco Ab PREBIOTIC THYLAKOID COMPOSITION
JP2015528506A (ja) 2012-09-13 2015-09-28 サリックス ファーマスーティカルズ，インコーポレーテッド 体重減少及び肥満の治療のためのリファキシミンの投与の方法
US11060148B2 (en) 2012-10-16 2021-07-13 Dana-Farber Cancer Institute, Inc. Diagnosing and treating colorectal cancer
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
US11135273B2 (en) * 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
RU2662932C2 (ru) 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CN105492611A (zh) 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
EP4023750A1 (en) 2013-07-01 2022-07-06 Massachusetts Institute of Technology Functionalization of endogenous bacteria
DE102013012448A1 (de) 2013-07-26 2015-01-29 Kuka Laboratories Gmbh Verfahren und Vorrichtung zum Bremsen einer Roboterachsanordnung
JP5729429B2 (ja) * 2013-07-29 2015-06-03 トヨタ自動車株式会社 接合構造、及び接合構造の製造方法
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
US9944925B2 (en) 2013-08-02 2018-04-17 Enevolv, Inc. Processes and host cells for genome, pathway, and biomolecular engineering
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
EP4074330A1 (en) 2013-09-05 2022-10-19 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
US20150070747A1 (en) * 2013-09-09 2015-03-12 Qualcomm Mems Technologies, Inc. Display element reset using polarity reversal
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
EP3988649B1 (en) 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
KR102308597B1 (ko) 2013-10-17 2021-10-01 내셔널 유니버시티 오브 싱가포르 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
US10752906B2 (en) 2013-11-05 2020-08-25 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
AU2014346846A1 (en) 2013-11-05 2016-06-09 Temple University Of The Commonwealth System Of Higher Education Polycationic amphiphiles as antimicrobial agents
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
WO2015070193A1 (en) 2013-11-11 2015-05-14 Liu Oliver Compositions and methods for targeted gene disruption in prokaryotes
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US20150157670A1 (en) * 2013-12-06 2015-06-11 K&K Ventures, LLC Non-caloric probiotic composition and method of preparation
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
JP6712948B2 (ja) * 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
US9676641B2 (en) 2014-01-29 2017-06-13 Synphagen Llc Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
US10287590B2 (en) 2014-02-12 2019-05-14 Dna2.0, Inc. Methods for generating libraries with co-varying regions of polynuleotides for genome modification
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015148680A1 (en) * 2014-03-25 2015-10-01 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering
EP3122880B1 (en) * 2014-03-26 2021-05-05 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
CN106170550A (zh) 2014-04-03 2016-11-30 麻省理工学院 用于产生导引rna的方法和组合物
JP2017512481A (ja) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
CN106536739B (zh) * 2014-04-14 2021-08-03 内梅西斯生物有限公司 治疗剂
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
WO2015189693A1 (en) 2014-06-12 2015-12-17 King Abdullah University Of Science And Technology Targeted viral-mediated plant genome editing using crispr/cas9
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
EP3186375A4 (en) 2014-08-28 2019-03-13 North Carolina State University Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING
US11274317B2 (en) 2014-09-05 2022-03-15 Vilnius University Targeted RNA knockdown and knockout by type III-A Csm complexes
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
WO2016063263A2 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
CN107208070B (zh) 2014-11-26 2021-09-07 技术创新动力基金（以色列）有限合伙公司 细菌基因的靶向消除
WO2016183532A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US20160244784A1 (en) 2015-02-15 2016-08-25 Massachusetts Institute Of Technology Population-Hastened Assembly Genetic Engineering
JP7095993B2 (ja) 2015-03-02 2022-07-05 シンロジック オペレーティング カンパニー インコーポレイテッド 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
CA2983236A1 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
EP3711488A1 (en) 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
ES2881384T3 (es) 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
US20160347836A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
EA201792663A1 (ru) 2015-05-29 2018-04-30 Норт Каролина Стейт Юниверсити Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
PE20180673A1 (es) 2015-06-01 2018-04-19 Univ Chicago Tratamiento contra el cancer por manipulacion de la microflora comensal
WO2016205276A1 (en) 2015-06-15 2016-12-22 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US20180200342A1 (en) 2015-07-13 2018-07-19 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
GB201514510D0 (en) 2015-08-14 2015-09-30 Nemesis Bioscience Ltd Delivery vehicle
KR102569754B1 (ko) 2015-09-10 2023-08-23 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 살균된 아커만시아의 용도
EP3356533A1 (en) 2015-09-28 2018-08-08 North Carolina State University Methods and compositions for sequence specific antimicrobials
EP3368696A1 (en) 2015-10-30 2018-09-05 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
EP3384016A4 (en) 2015-12-04 2019-04-24 Massachusetts Institute of Technology MANIPULATED PHAGEMIDES
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
US10828318B2 (en) 2016-01-06 2020-11-10 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
US20190010506A1 (en) 2016-01-11 2019-01-10 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US20190282628A1 (en) 2016-01-11 2019-09-19 Synlogic Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
WO2017123418A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
US20170247690A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Oncoviral treatment with nuclease and chemotherapeutic
WO2017152126A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
EP3448400A4 (en) 2016-04-25 2019-11-13 Yale University BACTERIOPHAGE COMPOSITIONS AND USES THEREOF
US20190136230A1 (en) 2016-05-06 2019-05-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
KR102708641B1 (ko) 2016-09-27 2024-09-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10626394B2 (en) 2016-10-28 2020-04-21 Massachusetts Institute Of Technology Synthetic bacteriophages and bacteriophage compositions
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
EP3559257A1 (en) 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
US11149269B2 (en) 2017-05-15 2021-10-19 New York University Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability
EP3634442B1 (en) 2017-05-24 2025-04-09 Tets, Viktor, Veniaminovich Method for diagnosis of parkinson's disease
EP3634465A4 (en) 2017-05-25 2021-01-20 The Broad Institute, Inc. LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF
EP3630975B1 (en) 2017-05-26 2025-11-19 North Carolina State University Altered guide rnas for modulating cas9 activity and methods of use
WO2018222969A1 (en) 2017-06-02 2018-12-06 Board Of Regents, The University Of Texas System Specific bacterial species and metabolite that improves immune checkpoint inhibitor therapy efficacy
US11453874B2 (en) 2017-06-07 2022-09-27 The Rockefeller University Enhancement of CRISPR gene editing or target destruction by co-expression of heterologous DNA repair protein
JP2020525049A (ja) 2017-06-25 2020-08-27 エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 微生物集団の変更及び細菌叢の改変
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US10303379B2 (en) 2017-09-25 2019-05-28 International Business Machines Corporation Efficient adaptive read-ahead in log structured storage
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3099316A1 (en) 2018-05-04 2019-11-07 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
US12076352B2 (en) 2018-06-19 2024-09-03 Glaxosmithkline Biologicals Sa Immunogenic composition
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
WO2020072254A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for killing target cells
WO2020072248A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
US20220056457A1 (en) 2018-12-11 2022-02-24 The University Of Western Ontario Cis conjugative plasmid system
KR102227515B1 (ko) 2018-12-18 2021-03-12 주식회사 포스코 제올라이트 및 그 제조방법
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
GB201912176D0 (en) 2019-08-23 2019-10-09 Snipr Biome Aps Plasmids
WO2021097118A1 (en) 2019-11-12 2021-05-20 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
US20230235361A1 (en) 2020-07-03 2023-07-27 Eligo Bioscience Method of containment of nucleic acid vectors introduced in a microbiome population
GB202015255D0 (en) 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses
FR3136482A1 (fr) 2021-08-01 2023-12-15 Snipr Biome Aps Ingenierie du microbiote
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
KR20250031203A (ko) 2022-06-29 2025-03-06 에스엔아이피알 바이옴 에이피에스. 이 콜라이 세포의 표적화
GB202212688D0 (en) 2022-08-31 2022-10-12 Snipr Biome Aps A novel type of crispr/cas system
EP4677075A2 (en) 2023-03-06 2026-01-14 SNIPR Biome ApS Targeting cells in stressed growing conditions
GB202310227D0 (en) 2023-07-04 2023-08-16 Snipr Biome Aps Production & secretion of auxin-like molecules in bacteria

Also Published As

Publication number Publication date
AU2016257306B2 (en) 2019-06-27
AU2022202944B2 (en) 2023-01-05
US12514869B2 (en) 2026-01-06
AU2025283440A1 (en) 2026-01-22
US20200205416A1 (en) 2020-07-02
US10463049B2 (en) 2019-11-05
US20220233575A1 (en) 2022-07-28
EP4545082A3 (en) 2025-07-02
US10524477B2 (en) 2020-01-07
US20160333348A1 (en) 2016-11-17
AU2019236694A1 (en) 2019-10-17
US20250228884A1 (en) 2025-07-17
JP2026009952A (ja) 2026-01-21
US9701964B2 (en) 2017-07-11
IL293646A (en) 2022-08-01
IL255427B (en) 2021-10-31
EP3711488A1 (en) 2020-09-23
RU2019130337A (ru) 2019-10-15
US11547716B2 (en) 2023-01-10
US20180146681A1 (en) 2018-05-31
IL293646B1 (en) 2024-03-01
RU2017142352A3 (https=) 2019-06-06
US20180084785A1 (en) 2018-03-29
JP2022106717A (ja) 2022-07-20
CN114099712A (zh) 2022-03-01
US20200068901A1 (en) 2020-03-05
US20180064114A1 (en) 2018-03-08
EP4233546A2 (en) 2023-08-30
US20210290654A1 (en) 2021-09-23
US20250186479A1 (en) 2025-06-12
EP3907285A1 (en) 2021-11-10
US20220241318A1 (en) 2022-08-04
EP4570253A2 (en) 2025-06-18
KR20230174291A (ko) 2023-12-27
KR20200091499A (ko) 2020-07-30
US20220273696A1 (en) 2022-09-01
CN107667173A (zh) 2018-02-06
EP3729967A1 (en) 2020-10-28
HK1245016A1 (zh) 2018-08-24
SI3291679T1 (sl) 2022-04-29
IL283877B (en) 2022-07-01
WO2016177682A1 (en) 2016-11-10
JP2018515138A (ja) 2018-06-14
IL310108B2 (en) 2025-05-01
EP4169383A1 (en) 2023-04-26
IL293646B2 (en) 2024-07-01
JP2020058369A (ja) 2020-04-16
IL310108B1 (en) 2025-01-01
US11517582B2 (en) 2022-12-06
CA2984975A1 (en) 2016-11-10
US20190133135A1 (en) 2019-05-09
US20250161345A1 (en) 2025-05-22
EP3563684A1 (en) 2019-11-06
IL283877A (en) 2021-07-29
AU2024202021A1 (en) 2024-04-18
US20220362280A1 (en) 2022-11-17
US11612617B2 (en) 2023-03-28
US20200085066A1 (en) 2020-03-19
DK3291679T3 (da) 2022-01-17
IL310108A (en) 2024-03-01
US11844760B2 (en) 2023-12-19
EP3291679B1 (en) 2021-12-15
JP2024038120A (ja) 2024-03-19
US20210145006A1 (en) 2021-05-20
US20210283167A1 (en) 2021-09-16
KR20180002776A (ko) 2018-01-08
IL255427A0 (en) 2017-12-31
RU2019130337A3 (https=) 2021-12-20
AU2016257306A1 (en) 2018-01-04
US20200077663A1 (en) 2020-03-12
EP3903586A1 (en) 2021-11-03
EP4005386A1 (en) 2022-06-01
KR20250107283A (ko) 2025-07-11
DE112016002056T5 (de) 2018-02-08
US20200128832A1 (en) 2020-04-30
CN121891567A (zh) 2026-04-21
US11147830B2 (en) 2021-10-19
EP4545082A2 (en) 2025-04-30
US20170246221A1 (en) 2017-08-31
EP3461337A1 (en) 2019-04-03
SG11201708706YA (en) 2017-11-29
US20170196225A1 (en) 2017-07-13
US10506812B2 (en) 2019-12-17
AU2019236694B2 (en) 2022-02-03
EP3291679A1 (en) 2018-03-14
AU2023202066B2 (en) 2024-04-18
AU2024202021B2 (en) 2025-09-25
KR102138209B1 (ko) 2020-07-28
RU2017142352A (ru) 2019-06-06
US11400110B2 (en) 2022-08-02
US10582712B2 (en) 2020-03-10
US12226430B2 (en) 2025-02-18
US20190230936A1 (en) 2019-08-01
US12514867B2 (en) 2026-01-06
US11642363B2 (en) 2023-05-09
EP4233546A3 (en) 2023-09-27
US10624349B2 (en) 2020-04-21
US20180070594A1 (en) 2018-03-15
US20200337313A1 (en) 2020-10-29
US20180064115A1 (en) 2018-03-08
US12502401B2 (en) 2025-12-23
US10561148B2 (en) 2020-02-18
US20180084786A1 (en) 2018-03-29
AU2022202944A1 (en) 2022-05-26
EP4570253A3 (en) 2025-08-20
NZ738068A (en) 2019-07-26
PL3291679T3 (pl) 2022-04-25
AU2023202066A1 (en) 2023-05-11
US20240082289A1 (en) 2024-03-14
US20210386773A1 (en) 2021-12-16
US20200267992A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
ES2905525T3 (es) Alteración de poblaciones microbianas y modificación de la microbiota
HK1245016B (en) Altering microbial populations & modifying microbiota